Huaibing He

(2<i>R</i>)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-<i>a</i>]pyrazin- 7(8<i>H</i>)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:  A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Dooseop Kim, Liping Wang, Maria Beconi et al. · Journal of Medicinal Chemistry · 2004 · 808 citations · Full text

Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes

George R. Lankas, Barbara Leiting, Ranabir Sinha Roy et al. · Diabetes · 2005 · 490 citations · Full text

Diabetes Management, Pharmacological Study, Biochemistry +15

Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy

Robert W. Myers, Hong-Ping Guan, Juliann Ehrhart et al. · Science · 2017 · 329 citations

Cardiac Muscle, Cardiovascular Pharmacology, Glucose Homeostasis +23

Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes

Tesfaye Biftu, Ranabir SinhaRoy, Ping Chen et al. · Journal of Medicinal Chemistry · 2014 · 167 citations · Full text

Medicinal Chemistry, Scientific Rationale, Available Dpp-4 Inhibitors +14

A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors

Thomas J. Tucker, Mark W. Embrey, Candice Alleyne et al. · Journal of Medicinal Chemistry · 2021 · 140 citations · Full text